Cyclic Therapeutics is built around a next-generation AI platform for the design of cyclic peptide therapeutics targeting challenging and previously undruggable protein targets. Our proprietary technology, originating from world-leading research at Stockholm University, enables structure-agnostic discovery using primary sequence data alone.

By integrating machine learning with evolutionary algorithms, we design optimized cyclic peptides incorporating non-natural amino acids, achieving precise binding and functional control. AI-driven structure prediction enables rational design of binders, inhibitors, and agonists for complex targets.

Cyclic Therapeutics has four therapeutic programs in development, supported by experimental validation across additional targets, and an active collaboration with a Top-10 pharmaceutical company. We are seeking discovery collaborations and co-development partnerships to expand the application of our AI platform.